{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T20:15:43Z","timestamp":1648844143098},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1007\/bf02938412","type":"journal-article","created":{"date-parts":[[2008,8,19]],"date-time":"2008-08-19T02:43:13Z","timestamp":1219113793000},"page":"224-233","source":"Crossref","is-referenced-by-count":2,"title":["Botulinum toxin in the management of dystonia"],"prefix":"10.1007","volume":"9","author":[{"given":"Omar D.","family":"Cardona-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald S.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Molho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF02938412_CR1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1176\/ajp.135.3.349","volume":"135","author":"RP Lesser","year":"1978","unstructured":"Lesser RP, Fahn S:Dystonia: a disorder often misdiagnosed as a conversion reaction.Am J Psychiatry 1978, 135:349\u2013352.","journal-title":"Am J Psychiatry"},{"key":"BF02938412_CR2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ng0997-40","volume":"17","author":"LJ Ozelius","year":"1997","unstructured":"Ozelius LJ, Hewett JW, Page CE, et al.:The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.Nat Genet 1997, 17:40\u201348.","journal-title":"Nat Genet"},{"key":"BF02938412_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870030107","volume":"3","author":"P Greene","year":"1988","unstructured":"Greene P, Shale H, Fahn S:Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.Mov Disord 1988, 3:46\u201360.","journal-title":"Mov Disord"},{"key":"BF02938412_CR4","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199104253241707","volume":"324","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Brin MF:Therapeutic uses of botulinum toxin.N Engl J Med 1991, 324:1186\u20131194.","journal-title":"N Engl J Med"},{"key":"BF02938412_CR5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","volume":"49","author":"MF Lew","year":"1997","unstructured":"Lew MF, Adornato BT, Duane DD, et al.:Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia.Neurology 1997, 49:701\u2013707.","journal-title":"Neurology"},{"key":"BF02938412_CR6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","volume":"37","author":"J Jankovic","year":"1987","unstructured":"Jankovic J, Orman J:Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.Neurology 1987, 37:616\u2013623.","journal-title":"Neurology"},{"key":"BF02938412_CR7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","volume":"46","author":"JW Brans","year":"1996","unstructured":"Brans JW, Lindeboom R, Snoek JW, et al.:Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.Neurology 1996, 46:1066\u20131072.","journal-title":"Neurology"},{"key":"BF02938412_CR8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Of major importance Comella CL, Jankovic J, Shannon KM, et al.:Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia.Neurology 2005, 65:1423\u20131429. Forst tandomized, blinded, head-to-head comparative study between toxin serotypes.","journal-title":"Neurology"},{"issue":"Suppl 2","key":"BF02938412_CR9","first-page":"252","volume":"66","author":"EJ Pappert","year":"2006","unstructured":"Of importance Pappert EJ, Leong MS, Royal MA:Botulinum toxin type B compared with type A in the treatment of toxin-naive patients with cervical dystonia: results from a randomized, double-blind study.Neurology 2006, 66(Suppl 2):252. Randomized, blinded, head-to-head comparison of botulinum toxins type A and B, currently vailable in abstract form.","journal-title":"Neurology"},{"key":"BF02938412_CR10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/WNL.42.4.878","volume":"42","author":"CL Comella","year":"1992","unstructured":"Comella CL, Buchman AS, Tanner CM, et al.:Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.Neurology 1992, 42:878\u2013882.","journal-title":"Neurology"},{"key":"BF02938412_CR11","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/mus.1185","volume":"24","author":"RL Barbano","year":"2001","unstructured":"Barbano RL:Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful.Muscle Nerve 2001, 24:1567\u20131568.","journal-title":"Muscle Nerve"},{"key":"BF02938412_CR12","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/mus.1186","volume":"24","author":"J Jankovic","year":"2001","unstructured":"Jankovic J:Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required.Muscle Nerve 2001, 24:1568\u20131570.","journal-title":"Muscle Nerve"},{"key":"BF02938412_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hed.2880140108","volume":"14","author":"GE Borodic","year":"1992","unstructured":"Borodic GE, Pearce LB, Smith K, et al.:Botulinum A toxin for spasmodic torticollis: multiple vs single injection points per muscle.Head Neck 1992, 14:33\u201337.","journal-title":"Head Neck"},{"key":"BF02938412_CR14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1212\/WNL.40.2.277","volume":"40","author":"J Jankovic","year":"1990","unstructured":"Jankovic J, Schwartz K:Botulinum toxin injections for cervical dystonia.Neurology 1990, 40:277\u2013280.","journal-title":"Neurology"},{"key":"BF02938412_CR15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.20290","volume":"20","author":"B Berman","year":"2005","unstructured":"Berman B, Seeberger L, Kumar R:Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.Mov Disord 2005, 20:233\u2013237.","journal-title":"Mov Disord"},{"key":"BF02938412_CR16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, et al.:Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.Mov Disord 2004, 19:303\u2013308.","journal-title":"Mov Disord"},{"key":"BF02938412_CR17","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000249308.66959.43","volume":"67","author":"J Jankovic","year":"2006","unstructured":"Jankovic J, Hunter C, Dolimbek BZ, et al.:Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.Neurology 2006, 67:2233\u20132235.","journal-title":"Neurology"},{"key":"BF02938412_CR18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J:Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia.Neurology 2003, 60:1186\u20131188.","journal-title":"Neurology"},{"key":"BF02938412_CR19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","volume":"53","author":"MF Brin","year":"1999","unstructured":"Brin MF, Lew MF, Adler CH, et al.Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.Neurology 1999, 53:1431\u20131438.","journal-title":"Neurology"},{"key":"BF02938412_CR20","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/mds.20531","volume":"20","author":"SA Factor","year":"2005","unstructured":"Factor SA, Molho ES, Evans S, Feustel PJ:Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.Mov Disord 2005, 20:1152\u20131160.","journal-title":"Mov Disord"},{"key":"BF02938412_CR21","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jnnp.53.8.640","volume":"53","author":"JD Blackie","year":"1990","unstructured":"Blackie JD, Lees AJ:Botulinum toxin treatment in spasmodic torticollis.J Neurol Neurosurg Psychiatry 1990, 53:640\u2013643.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02938412_CR22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, et al.:Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebocontrolled study.Mov Disord 2005, 20:783\u2013791.","journal-title":"Mov Disord"},{"key":"BF02938412_CR23","first-page":"459","volume":"72","author":"D Ranoux","year":"2002","unstructured":"Ranoux D, Gury C, Fondarai J, et al.:Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia.J Neurol Neurosurg Psychiatry 2002, 72:459\u2013462.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02938412_CR24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.iio.0000167238.26526.a8","volume":"45","author":"GJ Ben Simon","year":"2005","unstructured":"Ben Simon GJ, McCann JD:Benign essential blepharospasm.Int Ophthalmol Clin 2005, 45:49\u201375.","journal-title":"Int Ophthalmol Clin"},{"key":"BF02938412_CR25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/112067210601600202","volume":"16","author":"E Kerty","year":"2006","unstructured":"Kerty E, Eidal K:Apraxia of eyelid opening: clinical features and therapy.Eur J Ophthalmol 2006, 16:204\u2013208.","journal-title":"Eur J Ophthalmol"},{"key":"BF02938412_CR26","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1442-9071.2006.01236.x","volume":"34","author":"AL Pang","year":"2006","unstructured":"Pang AL, O\u2019Day J:Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?Clin Experiment Ophthalmol 2006, 34:441\u2013444.","journal-title":"Clin Experiment Ophthalmol"},{"key":"BF02938412_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1590\/S0004-282X2005000200006","volume":"63","author":"L Silveira-Moriyama","year":"2005","unstructured":"Silveira-Moriyama L, Goncalves LR, Chien HF, et al.:Botulinum toxin A in the treatment of blepharospasm: a 10-year experience.Arq Neuropsiquiatr 2005, 63:221\u2013224.","journal-title":"Arq Neuropsiquiatr"},{"key":"BF02938412_CR28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.parkreldis.2006.06.002","volume":"12","author":"DD Truong","year":"2006","unstructured":"Truong DD, Jost WH:Botulinum toxin: clinical use.Parkinsonism Relat Disord 2006, 12:331\u2013355.","journal-title":"Parkinsonism Relat Disord"},{"key":"BF02938412_CR29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2006.01441.x","volume":"13","author":"R Bhidayasiri","year":"2006","unstructured":"Bhidayasiri R, Cardoso F, Truong DD:Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.Eur J Neurol 2006, 13:21\u201329.","journal-title":"Eur J Neurol"},{"key":"BF02938412_CR30","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1212\/WNL.53.9.2102","volume":"53","author":"EK Tan","year":"1999","unstructured":"Tan EK, Jankovic J:Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up.Neurology 1999, 53:2102\u20132107.","journal-title":"Neurology"},{"key":"BF02938412_CR31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/archotol.127.4.389","volume":"127","author":"N Bhattacharyya","year":"2001","unstructured":"Bhattacharyya N, Tarsy D:Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia.Arch Otolaryngol Head Neck Surg 2001, 127:389\u2013392.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"BF02938412_CR32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/mds.10001","volume":"17","author":"CH Adler","year":"2002","unstructured":"Adler CH, Factor SA, Brin M, et al.:Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia.Mov Disord 2002, 17:158\u2013161.","journal-title":"Mov Disord"},{"key":"BF02938412_CR33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/00005537-200102000-00006","volume":"111","author":"A Blitzer","year":"2001","unstructured":"Blitzer A, Sulica L:Botulinum toxin: basic science and clinical uses in otolaryngology.Laryngoscope 2001, 111:218\u2013226.","journal-title":"Laryngoscope"},{"key":"BF02938412_CR34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1468-1331.2006.01443.x","volume":"13","author":"DD Truong","year":"2006","unstructured":"Truong DD, Bhidayasiri R:Botulinum toxin therapy of laryngeal muscle hyperactivity syndromes: comparing different botulinum toxin preparations.Eur J Neurol 2006, 13:36\u201341.","journal-title":"Eur J Neurol"},{"key":"BF02938412_CR35","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00005537-199810000-00003","volume":"108","author":"A Blitzer","year":"1998","unstructured":"Blitzer A, Brin MF, Stewart CF:Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.Laryngoscope 1998, 108:1435\u20131441.","journal-title":"Laryngoscope"},{"key":"BF02938412_CR36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/archotol.126.4.533","volume":"126","author":"ME Smith","year":"2000","unstructured":"Smith ME, Ford CN:Resistance to botulinum toxin injections for spasmodic dysphonia.Arch Otolaryngol Head Neck Surg 2000, 126:533\u2013535.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"BF02938412_CR37","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archneur.1996.00550070055012","volume":"53","author":"SL Pullman","year":"1996","unstructured":"Pullman SL, Greene P, Fahn S, et al.:Approach to the treatment of limb disorders with botulinum toxin A.Arch Neurol 1996, 53:617\u2013624.","journal-title":"Arch Neurol"},{"key":"BF02938412_CR38","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1742-1241.2005.00603.x","volume":"59","author":"NS Gordon","year":"2005","unstructured":"Gordon NS:Focal dystonia, with special reference to writer\u2019s cramp.Int J Clin Pract 2005, 59:1088\u20131090.","journal-title":"Int J Clin Pract"},{"key":"BF02938412_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1468-1331.2006.01446.x","volume":"13","author":"CP Das","year":"2006","unstructured":"Das CP, Dressler D, Hallett M:Botulinum toxin therapy of writer\u2019s cramp.Eur J Neurol 2006, 13:55\u201359.","journal-title":"Eur J Neurol"},{"key":"BF02938412_CR40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","volume":"78","author":"JJ Kruisdijk","year":"2007","unstructured":"Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al.:Botulinum toxin for writer\u2019s cramp: a randomised, placebocontrolled trial and one year follow up.J Neurol Neurosurg Psychiatry 2007, 78:264\u2013270.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BF02938412_CR41","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","volume":"17","author":"GY Hsiung","year":"2002","unstructured":"Hsiung GY, Das SK, Ranawaya R, et al.:Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.Mov Disord 2002, 17:1288\u20131293.","journal-title":"Mov Disord"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02938412\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02938412","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T22:58:38Z","timestamp":1558565918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02938412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BF02938412"],"URL":"https:\/\/doi.org\/10.1007\/bf02938412","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}